Novartis Pharma's (NVS.US) class 1 new drug approved for clinical use in rheumatoid arthritis.

According to the Wisdom Financial APP, on May 8th, the official website of the CDE showed that Novartis Pharmaceuticals (NVS.US) class 1 new drug PIT565 was approved for clinical use, focusing on rheumatoid arthritis. PIT565 is a novel CD3/CD19/CD2 triple antibody, which, compared to CD3 double antibodies, can overcome T cell exhaustion and increase the depth and duration of patient response by co-stimulating CD2 with PIT565.